The first round of IRA drug price negotiation is complete. The results are a preview of the program’s operating logic — and a planning input for every pharma company with a brand likely to face selection in future cycles. The data is in. The pattern is readable. The question now is how development, commercial, and BD teams adjust.
What the First Round Actually Showed
The ten drugs selected for the first negotiation cycle were chosen based on their Medicare Part D spend — a selection criterion that disproportionately targets high-volume, high-price brands without generic or biosimilar competition. The negotiated prices represented reductions of 38% to 79% below list price, though the actual net price impact was more modest for drugs that were already carrying substantial rebate loads in commercial channels.
The process revealed two critical dynamics. First, CMS negotiated aggressively and without the deference to manufacturer cost data that industry had hoped for. The agency’s Maximum Fair Price methodology effectively treated therapeutic alternatives as pricing constraints — meaning drugs in competitive classes faced lower negotiated prices than single-source drugs with no comparators. Second, the legal challenges to the program largely failed, establishing the constitutional viability of the negotiation framework for future cycles.
Selection Risk: Who Gets Chosen Next
Understanding selection risk is the most actionable output of the first negotiation cycle. The IRA’s selection criteria — Medicare spend, years since approval, absence of generic or biosimilar competition — create a predictable filter. Brands with high Medicare Part D volume, more than nine years post-small-molecule approval (or twelve years post-biologic approval), and no near-term competition face the highest selection probability.
Teams with assets in that risk zone need to model the P&L impact of a Maximum Fair Price scenario now — not when the selection notice arrives. The lead time between selection and effective date is roughly three years, but the commercial planning implications begin the moment selection becomes probable. Pipeline decisions, lifecycle management investments, and BD valuations for in-scope assets all need to incorporate negotiation risk explicitly.
The Lifecycle Management Implications
The IRA’s small molecule versus biologic timeline differential — nine years versus twelve years of negotiation protection — creates a structural incentive to develop biologics over small molecules in high-value indications. Whether this incentive is strong enough to shift pipeline strategy is debated, but it’s clearly present. Teams evaluating modality choices for next-generation assets in Medicare-heavy therapeutic areas should be running this math.
Fixed-duration treatment paradigms — where a course of therapy concludes rather than continuing indefinitely — partially mitigate negotiation exposure by limiting long-term Medicare spend concentration. Gene therapy’s one-time dosing model is structurally protected from IRA negotiation in ways that chronic disease brands are not. This is a real, if partial, advantage for certain modalities.
The BD and Portfolio Valuation Adjustment
For BD teams, IRA negotiation risk is now a standard diligence variable for any asset with meaningful Medicare exposure in a chronic indication. Deals struck before this calculus was fully incorporated may be carrying valuations that don’t reflect the negotiated price environment. Teams licensing or acquiring assets with late-lifecycle Medicare revenue should be discounting that revenue stream explicitly in their models — not treating it as equivalent to commercial net revenue.
The first negotiation cycle was the prototype. The program is permanent, the methodology is established, and the assets in scope expand with every new cycle. This is now a standard feature of the US drug pricing landscape, not a transitional event.
For broader drug pricing context, see our Drug Pricing & Market Access Hub.
